Tag: system

Sammanfattning

EINDHOVEN, The Netherlands, Aug. 06, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces the appointment of Lucas Buchanan as a non-executive member of its Board of Directors.

Highlights

Sanofi completes the acquisition of Vigil Neuroscience, Inc.

NEW YORK and NEW ORLEANS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 26, 2025 to file lead plaintiff applications in a securities class action lawsuit against Sable Offshore Corp. (NYSE: SOC), if they purchased the Company’s securities (1) between May 19, 2025 and June 3, 2025, both dates inclusive (the “Class Period”); and/or (2) pursuant and/or traceable to Sable’s May 21, 2025 secondary public offering (the “SPO”). This action is pending in the United States District Court for the Central District of California.

BEIJING, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Symposium on International Cooperation for Digital Product Passport (DPP) and International Standards for Entire Lifecycle Management," organized by Zhongguancun Industry & Information Research Institute of Two-Dimensional Code Technology (ZIIOT), International Identification Code Industry Alliance (ICA), and the IEC 63538 Working Group, concluded successfully in Beijing. It unveiled the groundbreaking MA-DPP Universal Framework V1.0, an open international public good, providing standardized solutions for global supply chain digital transformation while seeking worldwide partners for joint implementation to facilitate smooth and stable global supply chains.

PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).